Fate Therapeutics (FATE) Tops Q2 EPS by 13c
Tweet
Share
E-mail
Get Alerts FATE Hot Sheet
Join SI Premium – FREE
Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.33), $0.13 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $6.77 million versus the consensus estimate of $1.33 million.
For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
- Jefferies Starts FedEx Freight Holding Company (FDXF) at Buy
- Evercore ISI Downgrades Nike (NKE) to In Line
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
